3.24

0.61% -0.02

After Hours: 3.18 -0.06 -1.85%

Prelude Therapeutics Inc (PRLD)

Overview News Price History Option Chain Financials Discussions Forecast

Prelude Therapeutics Inc stock is traded at $3.24, with a volume of 72,156. It is down -0.61% in the last 24 hours and up +12.89% over the past month. Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Previous Close:

$3.26

Open:

$3.2

24h Volume:

72,156

Relative Volume:

0.19

Market Cap:

$204.13M

Revenue:

$12.14M

Net Income/Loss:

$-99.50M

P/E Ratio:

-2.3934

EPS:

-1.3537

Net Cash Flow:

$-56.37M

1W Performance:

+1.57%

1M Performance:

+12.89%

6M Performance:

+116.00%

1Y Performance:

+406.65%

1-Day Range:

$3.12

$3.3119

1-Week Range:

$2.83

$3.40

52-Week Range:

$0.6101

$4.22

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name

Prelude Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

(302) 467-1280

Address

175 INNOVATION BOULEVARD, WILMINGTON

Employee

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

PRLD's Discussions on Twitter

Compare PRLD vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRLD Prelude Therapeutics Inc	3.24	205.39M	12.14M	-99.50M	-56.37M	-1.3537
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-20-24	Downgrade	Barclays	Equal Weight → Underweight
Mar-13-24	Initiated	JMP Securities	Mkt Outperform
Feb-20-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-29-22	Initiated	Jefferies	Buy
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy
Apr-26-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Barclays	Overweight
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Goldman	Neutral
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight

View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

Mar 22, 2026

Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN

Mar 22, 2026

Marker Therapeutics (NASDAQ:MRKR) & Prelude Therapeutics (NASDAQ:PRLD) Financial Survey - Defense World

Mar 22, 2026

Mar 21, 2026

If You Invested $1,000 in Prelude Therapeutics Inc (PRLD) - Stock Titan

Mar 21, 2026

PRLD PE Ratio & Valuation, Is PRLD Overvalued - Intellectia AI

Mar 21, 2026

Mar 20, 2026

Value Recap: How do insiders feel about Prelude Therapeutics IncorporatedChart Signals & Community Consensus Trade Alerts - baoquankhu1.vn

Mar 20, 2026

Mar 17, 2026

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting - Yahoo Finance

Mar 17, 2026

Mar 16, 2026

Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline - MyChesCo

Mar 16, 2026

Mar 13, 2026

Prelude Therapeutics Inc. Files Form 8-K with SEC – Company Information and Legal Exhibit Details (March 12, 2026) - Minichart

Mar 13, 2026

Prelude Therapeutics Establishes New ATM Equity Offering Facility - The Globe and Mail

Mar 13, 2026

Mar 12, 2026

Prelude Therapeutics files to offer up to $25 million in stock through Jefferies By Investing.com - Investing.com South Africa

Mar 12, 2026

Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com

Mar 12, 2026

Mar 11, 2026

Prelude Therapeutics 2025 Annual Report: Precision Oncology Pipeline, Business Strategy, and Regulatory Overview - Minichart

Mar 11, 2026

Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet

Mar 11, 2026

ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet

Mar 11, 2026

Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat

Mar 11, 2026

Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus

Mar 11, 2026

Citizens raises Prelude Therapeutics price target on JAK2 potential By Investing.com - Investing.com Canada

Mar 11, 2026

Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - Sahm

Mar 11, 2026

Mar 10, 2026

PRLD: Pipeline refocused on JAK2 V617F and KAT6A, with strong funding and key Incyte partnership - TradingView

Mar 10, 2026

Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet

Mar 10, 2026

Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M - AlphaStreet

Mar 10, 2026